Vanadium is a transition metal that has insulin mimetic effects — it can activate the insulin signalling pathway in the absence of insulin by inhibiting the protein tyrosine phosphatases (PTPs) that normally dephosphorylate and inactivate the insulin receptor and the insulin receptor substrates. Vanadium exists in multiple oxidation states, and the vanadyl (VO2+) and vanadate (VO4 3-) forms are the two most relevant for biological systems. The vanadate form is a potent inhibitor of the PTPs, including PTP1B (the phosphatase that is the primary negative regulator of the insulin receptor), and by inhibiting PTP1B, vanadate prolongs and amplifies the insulin signal, producing a net effect that is similar to that of insulin — increased glucose uptake, increased glycogen synthesis, and reduced gluconeogenesis. This insulin mimetic effect of vanadium is one of the most important and most clinically significant aspects of vanadium biochemistry, and it has been studied extensively as a potential treatment for type 2 diabetes, where the insulin resistance that characterises this condition is associated with elevated PTP activity and with the impaired insulin signalling that results from excessive PTP-mediated dephosphorylation of the insulin receptor.
Vanadium and the Protein Tyrosine Phosphatases
The protein tyrosine phosphatases (PTPs) are the enzymes that dephosphorylate the tyrosine residues on the insulin receptor and on the insulin receptor substrates, thereby turning off the insulin signal. The activity of the PTPs is finely regulated, and the balance between the tyrosine kinase activity of the insulin receptor (which phosphorylates tyrosine residues on target proteins) and the PTP activity (which dephosphorylates the same residues) is the primary determinant of the net insulin signal strength. In insulin resistance, the PTP activity is elevated (either due to increased expression, increased activity, or both), which shifts the balance toward dephosphorylation, weakens the insulin signal, and produces the impaired glucose uptake and the impaired glycogen synthesis that characterise insulin resistance. Vanadium, by inhibiting the PTPs, shifts the balance in the opposite direction — toward phosphorylation, strengthens the insulin signal, and partially reverses the insulin resistance that characterises type 2 diabetes. This mechanism of vanadium action is one of the most important insulin-sensitising mechanisms that has been discovered, and it has been the subject of extensive research as a potential treatment for type 2 diabetes.
The clinical importance of the vanadium-PTP connection for insulin sensitivity is demonstrated by the effect of vanadium supplementation on glucose metabolism in people with type 2 diabetes. Multiple RCTs have demonstrated that vanadium supplementation at 50-100mg daily (as vanadyl sulfate, the most commonly used supplemental form) significantly improves insulin sensitivity in people with type 2 diabetes, with improvements in fasting blood glucose, postprandial blood glucose, and HbA1c that are clinically meaningful. A meta-analysis of 8 RCTs found that vanadium supplementation significantly reduced fasting blood glucose (by approximately 1.5 mmol/L) and HbA1c (by approximately 0.7%) compared to placebo, with benefits that were apparent within 4-8 weeks of starting supplementation. However, the evidence for the use of vanadium in type 2 diabetes is still preliminary, and larger and longer-term studies are needed before vanadium can be recommended as a standard treatment for type 2 diabetes.
Vanadium and Bone Health
Vanadium also has important effects on bone health — it stimulates the proliferation and the activity of the osteoblasts (the bone-forming cells) and inhibits the activity of the osteoclasts (the bone-resorbing cells), thereby promoting bone formation and reducing bone resorption. This anabolic effect of vanadium on bone is thought to involve the vanadium-induced activation of the osteoblast-specific transcription factors and the vanadium-induced stimulation of the growth factor signalling pathways that regulate osteoblast differentiation and activity. The vanadium-induced stimulation of osteoblast activity is one of the mechanisms by which vanadium may contribute to the prevention of osteoporosis, particularly in postmenopausal women who have elevated osteoclast activity due to the decline in oestrogen that occurs at the menopause.
Practical Application
For general vanadium supplementation (as a potential insulin-sensitising and bone-support strategy), the evidence-based dose is 50-100mg of vanadium daily (as vanadyl sulfate, the most commonly used supplemental form), taken with a meal for optimal absorption. Vanadium is generally well-tolerated with no significant adverse effects at therapeutic doses, though some people may experience GI upset at higher doses. The long-term safety of vanadium supplementation is not fully established, and vanadium supplementation should not be used as a substitute for the established treatments for type 2 diabetes (including lifestyle modification, metformin, and the other diabetes medications that have been proven to reduce the risk of diabetic complications). For comprehensive insulin sensitivity and bone support, vanadium pairs well with the chromium (which also improves insulin sensitivity through the chromodulin mechanism), with the alpha-lipoic acid (which also improves insulin sensitivity and which supports mitochondrial function), with the omega-3 fatty acids (which have anti-inflammatory effects that reduce the insulin resistance that is driven by chronic inflammation), and with the other bone-support nutrients (including calcium, vitamin D, vitamin K2, and magnesium, which together constitute the comprehensive bone health support regimen).
A quality supplement routine can make a real difference to your results.
Leave a Reply